NEW YORK--(BUSINESS WIRE)--Lev Pharmaceuticals, Inc. (OTCBB:LEVP) will host a live conference call and webcast today to discuss the results from its pivotal U.S. Phase III trial of C1 inhibitor, to be marketed as Cinryze™, for the prophylactic treatment of hereditary angioedema (HAE), also known as hereditary C1 inhibitor deficiency.
